Peptide-World Update, Autumn 2026: Approvals, Phase 3 Data and the First BPC-157 Trial Start

Among the already-approved incretin agents, late summer 2026 was mainly about new indications and new regions. On 28 Aug 2026 the FDA expanded the use of tirzepatide (Mounjaro) to reducing the risk of major adverse cardiovascular events in adults with type-2 diabetes and established cardiovascular disease. The basis was the large SURPASS-CVOT trial with around 13,300 participants. Important for context: the result was non-inferiority versus the active comparator dulaglutide – not superiority over placebo. The European agency EMA assessed the same application and in June 2026 explicitly did NOT recommend a corresponding EU indication; there the trial data only enter the product information. So the same event can turn out differently depending on the region. In parallel, the oral Wegovy tablet (oral semaglutide) was approved EU-wide by the European Commission on 16 Jul 2026 – following a positive CHMP opinion in May 2026. Per the manufacturer it is the first oral GLP-1 receptor agonist in tablet form for weight management in the EU; in the US this form had already been approved in late 2025.

• Tirzepatide: FDA approval of a cardiovascular indication (28 Aug 2026); the EMA declined the EU indication (June 2026).
• Non-inferiority against an active comparator is not the same as superiority over placebo.
• Oral Wegovy tablet: EU approval on 16 Jul 2026 (first oral GLP-1 for weight management in the EU).

Several highly effective candidates delivered more solid data in 2026 – yet remain investigational and unapproved. For the triple agonist retatrutide, the Phase 3 trial TRIUMPH-1 (adults with obesity without type-2 diabetes) was published peer-reviewed in the New England Journal of Medicine in late September 2026, with a peak of around 28% weight loss over 80 weeks versus placebo. The manufacturer reported two further Phase 3 trials (TRIUMPH-2 and -3) as successful on 23 Jul 2026 – those figures are so far company topline, i.e. manufacturer statements, not yet peer-reviewed. A submission to the FDA is planned, per the manufacturer, for early 2027. The glucagon/GLP-1 dual agonist survodutide met its goals in two Phase 3 obesity trials: SYNCHRONIZE-1 (topline 04/2026) and SYNCHRONIZE-2 (with type-2 diabetes), the latter published in the NEJM in early October 2026. The fixed combination CagriSema (cagrilintide plus semaglutide) was filed with the FDA for approval in late 2025; a decision is expected during 2026. In the head-to-head trial REDEFINE 4, however, CagriSema missed non-inferiority against tirzepatide. New on the map is petrelintide, a long-acting amylin analogue: Phase 2 data appeared in the Lancet Diabetes & Endocrinology, and a registrational Phase 3 programme (ZUPREME) started in September 2026.

• Retatrutide: TRIUMPH-1 peer-reviewed in the NEJM (around 28% over 80 weeks); TRIUMPH-2/-3 positive but company topline; FDA submission planned for Q1 2027.
• Survodutide: SYNCHRONIZE-1 and -2 successful; SYNCHRONIZE-2 published in the NEJM – still investigational.
• CagriSema: FDA application filed (decision expected 2026); missed non-inferiority against tirzepatide in REDEFINE 4.
• Petrelintide: amylin analogue with Phase 2 data (Lancet) and a started Phase 3 programme, ZUPREME.

For the 'wellness' peptides popular on social media, the human evidence has barely moved – but regulation all the more so. The FDA's Pharmacy Compounding Advisory Committee (PCAC) discussed seven unapproved peptides (BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, epitalon) on 23–24 Jul 2026 with regard to pharmacy compounding under §503A – a discussion by an advisory committee, not an approval and not a proof of efficacy. At the same time, on 24 Aug 2026 the FDA sent a warning letter to an online peptide seller over unapproved, misbranded products; despite a 'research use only' label, the agency treats such injectable products of unknown purity as de facto intended for human use and as a serious risk. And the WADA Prohibited List 2026 keeps peptide hormones and growth factors banned in sport. A genuine bright spot for the evidence: for BPC-157, what appears to be the first randomised, placebo-controlled human trial (Phase 1) was entered into a public trial registry in early September 2026. That is progress, but explicitly not yet a result: as of this article the trial was not even recruiting, and no data exist.

• The FDA PCAC discussed seven 'wellness' peptides for compounding (§503A) – a review, not an approval.
• FDA warning letter to a grey-market seller: injectable products of unknown purity = a serious risk.
• WADA 2026: peptide hormones and growth factors remain banned in sport.
• BPC-157: first randomised human trial registered – still not recruiting and without results.